Antibody-drug conjugates gain traction in China oncology market, says GlobalData

China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets

Immutep announces expansion of triple combination therapy in first-line non-small cell lung cancer

Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and IO-IO-chemo triple combinations

Thermo Fisher Scientific opens cell therapy facility at University of California

The San Francisco facility is part of Thermo Fisher’s global pharma services network of more than 15 locations supporting cell and gene therapies.

Pfizer acquisition of ADC trailblazer Seagen a worthy investment: GlobalData

Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.

Pfizer acquires Seagen for US$ 43 billion to battle cancer

Proposed combination enhances Pfizer’s position as a leading company in oncology

Moderna’s non-vaccine mRNA therapeutic set to generate $278 million in 2028 if approved, estimates GlobalData

According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year

Novartis maintains growth momentum; Confirms FY’22 Group guidance

Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.

Jacobio Pharma to collaborate with Merck on clinical trial of JAB-21822

This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated colorectal cancer.

Novartis unveils new focused strategy

Transformation to pure-play Innovative Medicines company nears completion

CellOrigin Biotech collaborates with Qilu Pharma to develop CAR-iMAC Cell Therapy